



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GPO 2001-090.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/654,770
Filing Date	August 21, 2003
First Named Inventor	HAN, Hee-Chul
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	102084-39581 CIP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ . Kind Code ⁵ (if known)			

Examiner Signature	Binh Tran	Date Considered	11/14/05
-----------------------	-----------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/654,770
Filing Date	August 21, 2003
First Named Inventor	HAN, Hee-Chul
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	102084-39581 CIP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>AT</i>		<p>Larsen et al., "Reduction in Locomotor Activity of Arthritic Rats as Parameter for Chronic Pain: Effect of Morphine, Acetylsalicylic Acid and Citalopram," <i>Acta Pharmacol. Et Toxicol.</i>, 57:345-351 (1985).</p> <p>Cain et al., "Pain-Related Disability and Effects of Chronic Morphine in the Adjuvant-Induced Arthritis Model of Chronic Pain," <i>Physiology & Behavior</i>, 62(1):199-205 (1997).</p> <p>Hallas et al., "Establishment of Behavioral Parameters for the Evaluation of Osteopathic Treatment Principles in a Rat Model of Arthritis," <i>JAOA</i>, 97(4):207-214 (1997).</p>	
		<p>Sluka et al. "Differential Effects of N-Methyl-D-Aspartate (NMDA) and non-NMDA Receptor Antagonists on Spinal Release of Amino Acids After Development of Acute Arthritis in Rats," <i>Brain Research</i>, 664:77-84 (1994).</p> <p>Lawand et al., "Nicotinic Cholinergic Receptors: Potential Targets for Inflammatory Pain Relief," <i>Pain</i>, 80:291-299, (1999).</p>	
		<p>Lu et al., "Gabapentin Attenuates Nociceptive Behaviors in a Acute Arthritis Model in Rats," <i>The Journal of Pharmacology and Experimental Therapeutics</i>, 290(1):214-219 (1999).</p>	
		<p>Okuda et al., "Arthritis Induced in Cat by Sodium Urate: A possible Animal Model For Tonic Pain," <i>Pain</i>, 18:287-297 (1984).</p>	
		<p>Clarke, K.A., "Differential Fore-and Hindpaw Force Transmission in the Walking Rat," <i>Physiology & Behavior</i>, 58(3): 415-419 (1995).</p>	
		<p>Clarke et al., "Gait Analysis in a Rat Model of Osteoarthritis," <i>Physiology & Behavior</i>, 62(5):951-954 (1997).</p>	
<i>BT</i>		<p>Schott et al., "Weight Bearing as an Objective Measure of Arthritic Pain in the Rat," <i>Journal of Pharmacological and Toxicological Methods</i>, 31(2):79-83 (1994).</p>	

Examiner Signature	<i>Binh Tran</i>	Date Considered	<i>11/14/05</i>
--------------------	------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.